ArticleScientific reports2026
Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing incidence and emergence of polymyxin-resistant Acinetobacter baumannii pose a significant threat to global public health. The presence of sub-minimal inhibitory concentration (sub-MIC) antibiotics during clinical treatment is inevitable and may drive the development of antibiotic resistance. Therefore, understanding the fitness costs and underlying mechanisms of resistance evolution under sub-MIC polymyxin B (PMB) is crucial for controlling the spread of PMB-resistant strains. In this study, PMB resistance evolved rapidly within 1-2 days in different A. baumannii strains and acquisition of PMB resistance altered the bacterial susceptibility to other antibiotics. All evolved strains suffered varying degrees of fitness costs, manifesting as a reduced growth rate, in vitro competitiveness, motility ability, biofilm formation, and adhesion and invasion to host cells. Proteomic and qRT-PCR analyses revealed upregulation of efflux pumps, two-component systems and outer membrane proteins in resistant strains, along with downregulation of genes involved in lipid A biosynthesis, motility and biofilm formation. Notably, the increasing PMB resistance was attenuated upon co-treatment with efflux pump inhibitor CCCP. This study indicates that evolution of PMB resistance incurs substantial fitness costs in A. baumannii, and the loss of LPS production and overexpression of efflux pumps may represent the key mechanisms underlying this evolutionary process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.